Intraleucocyte platelet‐activating factor levels in desmopressin‐treated patients with haemophilia A and von Willebrand disease

Kavaklı, Kaan; Hüseyinov, Afig; Çoker, Işıl; Aydınok, Yeşim; Nişli, Güngör

doi:10.1046/j.1365-2516.2001.00535.x

Cited by 3 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood monocytes possess V2 receptors and can bind DDAVP (Block et al , 1981), and Hashemi et al (1990, 1993) have shown that monocytes exposed to DDAVP release platelet‐aggregating factor (PAF) into culture supernatants, which in turn induces the release of VWF from endothelial cells. Consistent with these in vitro findings, increased levels of PAF have been found within leucocytes after administration of DDAVP to patients with haemophilia A or VWD (Kavakli et al , 2001). All these findings suggest that intercellular messengers, secreted by monocytes, may play a role in the haemostatic effect of DDAVP.…”

supporting

confidence: 74%

DDAVP enhances the ability of blood monocytes to form rosettes with activated platelets by increasing the expression of P‐selectin sialylated ligands on the monocyte surface

Pereira¹,

Onorato²,

Sanz³

2003

Br J Haematol

View full text Add to dashboard Cite

Summary. The mechanism through which DDAVP (1-deamino-8-d-arginine vasopressin) promotes blood coagulation is not completely understood. As blood monocytes have been identified as a target for DDAVP, we investigated whether this drug increased monocyte adhesion to activated platelets, which would result in the close intercellular contact that is necessary for a juxtacrine effect on platelets and/or endothelium at sites of vascular injury. Monolayers of nonconfluent monocytes adhered to glass slides were incubated with thrombin-activated, formaldehyde-fixed platelets before and after the adherent monocytes were stimulated with DDAVP or n-formyl-methyl-leucyl-phenylalanine (fMLP). The number of platelets involved in rosettes with monocytes was quantified, and the effect of DDAVP or fMLP on the monocyte surface expression of P-selectin ligands and CD11b/CD18 was assessed. DDAVP or fMLP increased the number of activated platelets involved in rosettes with monocytes by 2AE8-and 4AE9-fold respectively. EDTA and inhibitors of the P-selectin/counter-receptor interaction decreased the platelet numbers in rosettes by 80-90%, whereas inhibitors of the integrin-mediated adhesion reduced rosettes by 40-50%. Blocking the P-selectin glycoprotein ligand-1 (PSGL-1) with the monoclonal antibody, Pl-1, decreased the platelet numbers in rosettes by only 50%. In contrast, surface expression of the sialylated ligands of P-selectin and, to a lesser extent, of CD11b/CD18 increased upon monocyte activation with DDAVP or fMLP, whereas it decreased slightly with PSGL-1. These results indicate that DDAVP enhanced the ability of blood monocytes to bind activated platelets, mainly by increasing the expression of P-selectin sialylated ligands on the monocyte surface. A similar effect was achieved with fMLP.

show abstract

supporting

confidence: 74%

DDAVP enhances the ability of blood monocytes to form rosettes with activated platelets by increasing the expression of P‐selectin sialylated ligands on the monocyte surface

Pereira¹,

Onorato²,

Sanz³

2003

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…Mannucci in 1997 reported that a FVIII:C level of ‡0.30 U mL )1 is sufficient to treat minor bleeds or to prevent bleeding in minor surgery [17]. Others have suggested that to be labelled as responders to DDAVP, patients need to attain a FVIII:C level of at least 0.50 U mL )1 [18,19]. In this study, we defined responders to DDAVP as those patients achieving a FVIII:C level of ‡0.30 U mL )1 one-hour post DDAVP infusion.…”

Section: Definition Of Ddavp Responsementioning

confidence: 99%

DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII:C level and with haemophilic genotype

2011

View full text Add to dashboard Cite

In most individuals with moderate/mild haemophilia A, FVIII:C levels increase following DDAVP administration to a haemostatic range, thus avoiding the need for FVIII concentrates. We sought to determine the relationship between responsiveness to DDAVP in boys (<18 years old) with mild/moderate haemophilia and patient age, haemophilic severity and haemophilic genotype. Our cohort consisted of 13 boys with moderate and 61 boys with mild haemophilia who, between them, had 38 different mutations; 21 had unique mutations not shared by any other clinic patient, whereas 53 shared one of 17 mutations with some other clinic patient (included 26 boys with ≥ 1 haemophilic brother). Patient age and endogenous FVIII:C levels were strong predictors of response to DDAVP. Younger patients responded less well to DDAVP and 10 of the 11 patients, when retested at an older age, showed an improved response to DDAVP. Only 1 patient with moderate haemophilia responded to DDAVP, whereas 80% of patients with mild haemophilia responded (including all patients with an endogenous FVIII:C of >0.15 U mL(-1)). Almost all patients with the same mutation had the same response to DDAVP or only a minor discordance in response. Patient's age, disease severity and genotype all are predictors of response to DDAVP.

show abstract

“…It was also suggested that some are derived from WBC, such as platelet-activating factor (PAF), interleukin (IL)-6, or P-selectin (Hashemi et al 1993, Mannucci 1997. In particular, PAF is a potent activator of both WBC and PLT (Kavakli et al 2001), and P-selectin plays an important part in the "rolling" of polymorphonuclear leucocytes (PMN), as demonstrated in the mesenteric venules of rats (Kanwar et al 1995).…”

Section: Discussionmentioning

confidence: 99%

Effect of desmopressin on hemochromocytometric and clotting parameters in healthy blood donor dogs

Giudice¹,

Giannetto²,

Casella³

et al. 2009

JAB

View full text Add to dashboard Cite

Six clinically healthy blood donor dogs were used to evaluate the effect of desmopressin (DDAVP) on haemochromocytometric and clotting parameters,. They received subcutaneously a physiological solution (placebo) and DDAVP (1μg/kg) with a two-weeks wash-out period between treatments. Blood samples were collected immediately before the injection, after 30 minutes, then after 1, 2, 3, 4, 5 and 6 hours. Two-way repeated measure analysis of variance (ANOVA) showed no significant effect of DDAVP vs placebo, except for white blood cell (WBC) count, and in particular on neutrophils. In conclusion, DDAVP administration in healthy donor dogs does not induce modification in blood cell count and clotting parameters, except of WBC.

show abstract

Intraleucocyte platelet‐activating factor levels in desmopressin‐treated patients with haemophilia A and von Willebrand disease

Cited by 3 publications

References 24 publications

DDAVP enhances the ability of blood monocytes to form rosettes with activated platelets by increasing the expression of P‐selectin sialylated ligands on the monocyte surface

DDAVP enhances the ability of blood monocytes to form rosettes with activated platelets by increasing the expression of P‐selectin sialylated ligands on the monocyte surface

DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII:C level and with haemophilic genotype

Effect of desmopressin on hemochromocytometric and clotting parameters in healthy blood donor dogs

Contact Info

Product

Resources

About